Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

ANI Pharmaceuticals (ANIP) stock in plain English

Free brief · no signupStart here
ANIPPublished Nov 14, 2026
ANI Pharmaceuticals Inc
Healthcare · Drug Manufacturers - Specialty & Generic
Sells specialty pharmaceuticals and generic prescription medications directly to wholesalers and health systems.
Assets:
Cortrophin GelPurified corticotropin injection targeting acute autoimmune flare-ups
Baudette manufacturing plantPrimary solid dose and liquid production facility in Minnesota
Duloxetine genericDelayed-release capsules equivalent to Cymbalta for depression and pain
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

77
OPS ScoreOperating finances
Latest quote
-3.27%$69.13
$1.57B
13.8×
$1.04B

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 14, 2026Quotes updated Nov 20, 04:00 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was ANIP. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does ANI Pharmaceuticals (ANIP) do?

ANI Pharmaceuticals Inc (ANIP) is a U.S.-listed company in Healthcare (Drug Manufacturers - Specialty & Generic). What it does: Sells specialty pharmaceuticals and generic prescription medications directly to wholesalers and health systems. Commercializes niche rare disease therapies while manufacturing high-volume generic prescription drugs in domestic. It is worth $1.57B on the market and sold $1.04B over the last year.

Market cap
$1.57B
P/E ratio
13.8×
Annual sales
$1.04B
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Brief updated
Nov 14, 2026

Brands and businesses behind ANIP

  • Cortrophin Gel: An adrenocorticotropic hormone injection prescribed for autoimmune flare-ups, sold through specialty pharmacies.
  • Iluvien: An intravitreal implant that releases corticosteroid to treat diabetic macular edema, earning revenue from retina specialists.
  • Yutiq: A micro-insert delivering fluocinolone acetonide to treat chronic non-infectious uveitis affecting the back of the eye.

ANIP’s flags, in plain English

Each flag is a number from ANI Pharmaceuticals’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 14, 2026.

Still Climbing

Sales up 33.5% a year over 5 years. Sales are higher than a year ago. Growth does not guarantee profit, so look at the margins too.

Growth vs Price

The price looks reasonable for how fast it is growing. The price looks reasonable for how fast its profits are growing.

Cheap on Cash Flow

Priced at 7.7 times the cash it generates each year. The share price is low compared with the cash the business actually brings in, and cash is harder to dress up than profit.

Heavily Shorted

18% of tradable shares are bet against (sold short). A large share of the stock has been borrowed and sold by traders betting it will fall. That can be a warning, and it can also push the price up fast if they rush to buy it back.

2 more green flags and 1 more risk note open with the free trial. Try it free for 7 days.

Questions about ANIP

How big is ANI Pharmaceuticals?

ANI Pharmaceuticals’ market cap is $1.57B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $1.04B: what customers paid the company over the last year, before any costs.

What is ANIP’s P/E ratio?

ANIP’s P/E ratio is 13.8×. Investors pay about 13.8 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with ANIP?

Lowered annual revenue targets for Cortrophin Gel reflect mounting payer pushback and restrictions across specialty pharmacy networks. That is one risk on ANI Pharmaceuticals’ card. Its first risk flag is Heavily Shorted, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From ANI Pharmaceuticals’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. ANIP’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card